Collegium Pharmaceutical earnings ahead after ADHD acquisition By Investing.com
Investing.com Nigeria
Collegium Pharmaceutical reported earnings beats following its acquisition of an ADHD treatment. The financial results exceeded expectations due to this strategic expansion into the ADHD market. This move highlights the company's focus on growing its portfolio in specialized therapeutic areas.
All articles from 6 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.